Barbara Weber, Tango Therapeutics CEO

Daniel O’Day’s I/O dance con­tin­ues, as Gilead and Tan­go ex­pand deal up to $6B

Three years ago, Gilead CEO John Mil­li­gan signed a mile­stone-heavy deal with a lit­tle-known biotech that had flashy tech­nol­o­gy and flashier founders. Now, with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.